Lantheus Holdings (LNTH)
DETREND PRICE OSCILLARTOR
Trading: BUY @ $16.01
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Lantheus Holdings (NASDAQ:LNTH) currently has a confirmed uptrend. Price is currently above the displaced moving average for LNTH Currently, the return on DPO20 is -1.8%.
The Detrended Price Oscillator (DPO) is an indicator designed to remove trend from price and make it easier to identify cycles. DPO does not extend to the last date because it is based on a displaced moving average. However alignment with the most recent is not an issue because DPO is not a momentum oscillator. Instead DPO is used to identify cycle’s highs/lows and estimate cycle length.
Calculation: Detrended Price Oscillator (DPO):
1) Price (X/2 + 1) periods ago minus X-period simple moving average.
Where X is the number of periods;
PROFILE: Lantheus Holdings (LNTH)
Stock Exchange: NASDAQ
Company: Lantheus Holdings
Ticker Codes: | LNTH | NASDAQ:LNTH |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Detrended Price OscillatorDownload
|BCRX BioCryst Pharmaceuticals||8.7||6||1,142,989||1.61||BULLISH|
|ADI Analog Devices||89.02||4.1||6,512,898||5.58||BULLISH|
|AMAT Applied Materials||35.77||3.9||25,063,667||2.11||BULLISH|
|AGEN Agenus Inc||2.16||3.3||1,083,584||0.31||BULLISH|
|LGIH Lgi Homes Inc||43.14||2.9||302,527||2.36||BULLISH|
|FORM Formfactor Inc||14.58||2.8||965,235||1.79||BULLISH|
|EMCI EMC Insurance||32.22||2.8||94,073||8.31||BULLISH|
|MCRB Seres Theraptc||8.23||2.7||61,812||1.62||BULLISH|
|MSEX Middlesex Water||50.1||2.3||53,276||4.6||BULLISH|
|ENTA Enanta Pharmaceutica||80.07||2.3||176,019||2.9||BULLISH|